140 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
and arrangements we could lose rights that are important to our business; the fact that Fortress Biotech, Inc. controls a majority of the voting power of our
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants annually; and
the risks described under … minutes from the Type C meeting with the FDA. The Type C meeting minutes indicate that the FDA and the Company are in agreement with a majority
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
, Inc. (“Fortress”) controls a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants … with a majority of the proposed protocol items and are in active discussion about remaining open items. The minutes indicate that the FDA also agrees
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest … appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company
8-K
EX-4.3
7hjvp
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-10.1
jonp80oii1 isrmzvf2
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-99.1
lubufh8 meoaq
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.1
7bzz5ix jrtxd
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-3.1
tcgou
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
8-K
EX-99.1
c4c56exs2gpa
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
DEF 14C
o13x9c
18 Mar 24
Information statement
4:59pm
8-K
EX-99.1
paekwadkgj
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
PRE 14C
spn16lowg2q
8 Mar 24
Preliminary information
4:31pm
8-K
x7zfj1yy h8kk
8 Mar 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
c1scm9w2fl
23 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
EX-3.1
ys6dlbcrqalm5ikubt6
23 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:17pm